Khosla Ventures

VitroLabs is a startup working on the cutting edge of 3D tissue engineering using stem cell-based technologies. The company develops fully scalable tissue engineering platform combining the latest breakthroughs in stem cell research, and biomaterials. It manufactures real leather without the need to raise and slaughter animals using breakthroughs in stem cell research and tissue engineering. VitroLabs was founded on 2016 and is based in San Jose, California.

Turn Biotechnologies is a Stanford spinout developing therapies to effectively return mature differentiated cells to a dramatically younger state leaving their differentiated identity unaltered. ​Turn Biotechnologies surpasses traditional approaches based on single gene/pathway manipulations and tackles the multifaceted manifestation of cellular age at the organ, tissue, and organismal level to extend the healthspan of people. As a result, age is reset by epigenetically reprogramming cells.

Volta Labs, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on engineering and developing tools for biological automation. Founded in 2018, the company specializes in creating scalable automation solutions for genetic engineering, aiming to enhance efficiency and precision in biological research and applications.

Cellino Biotech, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. The company specializes in developing intracellular delivery lasers and nanotechnology for gene editing applications. By leveraging advanced tools from optics, biology, and computation, Cellino transforms the process of stem cell differentiation into a digital format, allowing for the engineering of functionally mature cells. This innovative approach significantly accelerates the development time of engineered cells, reducing it from years to weeks.

Cambridge Glycoscience is a biotechnology company based in London, United Kingdom, founded in 2017. The company specializes in developing sugar-free ingredients for the food industry, focusing on creating natural food components derived from agricultural resources. Their innovative products enable food manufacturers to reduce sugar content, enhance fiber levels, and improve gut health-promoting qualities in food items. By leveraging biotechnology, Cambridge Glycoscience aims to support healthier eating options and contribute to the evolving landscape of food production.

Known Medicine is looking to take the experimentation of how tumors respond to cancer drugs out of the patient’s body and into the lab. The startup breaks down tumor samples into micro tumors, which they treat separately inside specialized micro-environments with different methods and see what works best.

Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body. Ochre Bio is within the heart of Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market.

Turn Biotechnologies is a Stanford spinout developing therapies to effectively return mature differentiated cells to a dramatically younger state leaving their differentiated identity unaltered. ​Turn Biotechnologies surpasses traditional approaches based on single gene/pathway manipulations and tackles the multifaceted manifestation of cellular age at the organ, tissue, and organismal level to extend the healthspan of people. As a result, age is reset by epigenetically reprogramming cells.

Cambridge Glycoscience is a biotechnology company based in London, United Kingdom, founded in 2017. The company specializes in developing sugar-free ingredients for the food industry, focusing on creating natural food components derived from agricultural resources. Their innovative products enable food manufacturers to reduce sugar content, enhance fiber levels, and improve gut health-promoting qualities in food items. By leveraging biotechnology, Cambridge Glycoscience aims to support healthier eating options and contribute to the evolving landscape of food production.

Cellino Biotech, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. The company specializes in developing intracellular delivery lasers and nanotechnology for gene editing applications. By leveraging advanced tools from optics, biology, and computation, Cellino transforms the process of stem cell differentiation into a digital format, allowing for the engineering of functionally mature cells. This innovative approach significantly accelerates the development time of engineered cells, reducing it from years to weeks.

Gen1E Lifesciences is a developer of a platform designed to accelerate cures for inflammatory and age-related diseases.The company's services include a pipeline of preclinical stage products that includes a P38 kinase inhibitor for the treatment of various inflammatory diseases, enabling medical researchers to optimize existing regulatory incentives, reduce the required R&D time and cost, truncate the time to exit and improve the success rate in receiving FDA approval and commercial success.

Cellino Biotech, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. The company specializes in developing intracellular delivery lasers and nanotechnology for gene editing applications. By leveraging advanced tools from optics, biology, and computation, Cellino transforms the process of stem cell differentiation into a digital format, allowing for the engineering of functionally mature cells. This innovative approach significantly accelerates the development time of engineered cells, reducing it from years to weeks.

BIOAGE discovers and develops drugs to treat aging and associated diseases.

Luminostics, Inc. develops a smartphone-based adaptor to access molecular-level health information through 15-minute DIY disease testing. It serves healthcare professionals and consumers. The company was incorporated in 2015 and is based in Houston, Texas.

At 20n, They use algorithms to engineer microbes. Specifically, their algorithms engineer microbes to make chemicals. Like yeast produces alcohol during beer brewing, their engineered microbes will produce chemicals with therapeutic health and industrial biotech applications. The best illustration of this DARPA-backed technology is the bacteria They engineered to produce Paracetamol (also known as acetaminophen, and sold under the brand name Tylenol). Aside from this bacteria, there is no known natural way of producing acetaminophen. They are building data mining technology that will allow us to enable the bioproduction of a whole spectrum of valuable molecules. Below is the map of every chemical that can be made biologically, as discovered by 20n's algorithms.

GreenLight Biosciences is a biotechnology company that specializes in RNA-based solutions for agricultural and pharmaceutical applications. Founded in 2008 and headquartered in Medford, Massachusetts, with an additional location in North Carolina, the company utilizes its Unconstrained Metabolism technology platform to convert renewable substrates into valuable chemicals and fuels. This platform allows for significant flexibility and control in the production process. GreenLight is also focused on developing RNA products aimed at improving crop management, plant protection, and animal health, while advancing vaccine development and pandemic preparedness. In addition to these applications, the company is working on mRNA-based vaccine candidates targeting seasonal and pandemic influenza, as well as other emerging viruses, to enhance public health. Through its innovations, GreenLight aims to provide sustainable solutions that contribute to global food security and health.